LAX.SH
UNICHEM LABORATORIES LTD·PHARMACEUTICALS 70.24·Pharmaceuticals & Biotechnology Companies
Price
526.15
+1.85%52W Range
Market Cap
₹3,704.40 Cr
Traded: ₹3.44 Cr (0.09%) 0.0x
Free Float: ₹643.45 Cr (0.53% of FF traded)
Volume · 60D trend
65.55 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | +11.0% | +0.0% | +2.0% | -- | -- | Stable |
| Return | +7.0% | +14.0% | +12.0% | +16.0% | -- | Stable |
| Profit | -3.0% | +25.0% | +35.0% | -- | -2.0% | Stable |
| Sales | +5.0% | +12.0% | +18.0% | -- | +7.0% | Stable |
Quarterly Results
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 633 | 575 | 521 | 579 | 527 | 587 | 533 | 507 | 483 | 432 | 466 | 416 | 423 | 402 | 302 | 329 |
| Expenses | 563 | 527 | 476 | 513 | 504 | 503 | 448 | 452 | 443 | 406 | 435 | 407 | 395 | 386 | 345 | 347 |
| Operating Profit | 70 | 48 | 45 | 66 | 22 | 84 | 86 | 55 | 40 | 25 | 31 | 9 | 28 | 16 | -43 | -18 |
| OPM % | 11.0% | 8.0% | 9.0% | 11.0% | 4.3% | 14.0% | 16.0% | 11.0% | 8.0% | 6.0% | 7.0% | 2.1% | 7.0% | 4.0% | -14.0% | -6.0% |
| Other Income | 16 | 11 | 287 | -37 | 7 | 9 | 14 | 9 | 4 | -119 | 79 | 6 | 9 | -28 | 16 | 4 |
| Interest | 7 | 9 | 7 | 8 | 7 | 5 | 7 | 5 | 4 | 5 | 6 | 7 | 6 | 6 | 4 | 5 |
| Depreciation | 30 | 31 | 31 | 31 | 32 | 30 | 31 | 32 | 32 | 27 | 32 | 29 | 29 | 30 | 31 | 28 |
| Profit Before Tax | 49 | 19 | 293 | -11 | -9 | 58 | 62 | 27 | 8 | -126 | 73 | -22 | 2 | -47 | -61 | -47 |
| Tax % | 15.0% | 42.0% | 10.0% | 10.0% | 16.0% | 8.0% | 6.0% | 9.0% | 74.0% | 3.0% | 0.0% | 12.0% | 132.0% | -6.0% | 4.0% | 50.0% |
| Net Profit | 41 | 11 | 264 | -12 | -10 | 53 | 58 | 25 | 2 | -129 | 73 | -24 | -1 | -44 | -64 | -71 |
| Exceptional Items | -- | -12 | 276 | -58 | 0 | 0 | 0 | 0 | 0 | -126 | 68 | 0 | 0 | -34 | 0 | -5 |
| EPS (Rs) | 5.9 | 1.6 | 37.5 | -1.7 | -1.5 | 7.5 | 8.2 | 3.5 | 0.3 | -18.4 | 10.4 | -3.5 | -0.1 | -6.3 | -9.1 | -10.0 |
| Sales Growth (YoY) | 20.1% | -2.0% | -2.3% | 14.2% | 9.1% | 35.9% | 14.4% | 21.9% | 14.2% | 7.5% | 54.3% | 26.4% | -- | -- | -- | -- |
| Sales Growth (QoQ) | 10.1% | 10.4% | -10.0% | 9.9% | -10.2% | 10.1% | 5.1% | 5.0% | 11.8% | -7.3% | 12.0% | -1.6% | 5.2% | 33.1% | -8.2% | -- |
| OP Growth (YoY) | 218.2% | -42.9% | -47.7% | 20.0% | -45.0% | 236.0% | 177.4% | 511.1% | 42.9% | 56.3% | 172.1% | 150.0% | -- | -- | -- | -- |
| OP Growth (QoQ) | 45.8% | 6.7% | -31.8% | 200.0% | -73.8% | -2.3% | 56.4% | 37.5% | 60.0% | -19.4% | 244.4% | -67.9% | 75.0% | 137.2% | -138.9% | -- |
| Profit Growth (YoY) | -- | -66.0% | -70.0% | 84.0% | -606.0% | 844.0% | 742.0% | 201.0% | 409.0% | 43.0% | 111.0% | 64.0% | 97.0% | -117.0% | -353.0% | -432.0% |
| EPS Growth (YoY) | 495.3% | -79.4% | 356.7% | -148.3% | -613.8% | 140.9% | -21.0% | 200.6% | 390.0% | -192.1% | 214.5% | 65.3% | -- | -- | -- | -- |
| EPS Growth (QoQ) | 280.0% | -95.9% | 2321.3% | -13.4% | -119.8% | -8.5% | 134.9% | 1106.9% | 101.6% | -276.6% | 398.9% | -3380.0% | 98.4% | 30.7% | 9.6% | -- |
| OP Margin | 11.1% | 8.3% | 8.6% | 11.4% | 4.2% | 14.3% | 16.1% | 10.8% | 8.3% | 5.8% | 6.7% | 2.2% | 6.6% | 4.0% | -14.2% | -5.5% |
| Net Margin | 6.5% | 1.9% | 50.7% | -2.1% | -1.9% | 9.0% | 10.9% | 4.9% | 0.4% | -29.9% | 15.7% | -5.8% | -0.2% | -10.9% | -21.2% | -21.6% |
| Material Cost % | -- | 46.6% | 45.5% | 46.7% | 46.5% | 45.1% | 35.9% | 42.3% | 39.9% | 38.7% | 42.0% | 39.2% | 39.8% | 43.1% | 45.6% | 39.4% |
| Employee Cost % | -- | 16.1% | 19.1% | 17.3% | 20.4% | 16.4% | 19.1% | 20.1% | 21.1% | 23.0% | 21.9% | 23.3% | 23.4% | 22.1% | 29.9% | 27.2% |
| P/S | 1.61 | 1.62 | 1.15 | 1.09 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 12.15 | 14.12 | 8.67 | 27.56 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 1.36 | 1.31 | 1.05 | 1.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Disclosure of Voting Results alongwith Scrutinizer''s Report dated 12th August 2026.
Financial Results for the quarter ended June 30, 2026, published in the newspapers on August 12, 2026.
Proceedings of the 63rd Annual General Meeting.
Pl. find enclosed financial statement of FY 2026-2027 (CFS & SFS)
Unaudited Financial Statements (Consolidated & Standalone) for the first quarter ended 30th June 2026 alongwith Limited Review report by Auditors
Pl. find attached response to clarification sought on price movement
The Exchange has sought clarification from Unichem Laboratories Ltd on July 10, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
Compliance Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018, for the quarter ended June 30, 2026
Intimating to shareholders - Non-email cases
Issued letters to those shareholders whose email address are not registered with the Company/Depository Particeipant/ Registrar and Share Transfer Agent, Providing the web-link from where ....
Newspaper publication regarding e-voting information for 63rd Annual General Meeting of the Company.
Annual Report FY 2026
Business Responsibility and Sustainability Report for FY 2026
Notice of 63rd AGM - 11th August 2026
Intimation of Closure of Trading WIndow.
Notice issued in the newspapers on 16th June 2026 in terms of Circular No. 20/2020, 5th May 2020, issued by the Ministry of Corporate Affairs.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Equity Intelligence India Pvt Ltd
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Equity Intelligence India Pvt Ltd
The Exchange has sought clarification from Unichem Laboratories Ltd on June 11, 2026, with reference to Movement in Volume.<BR><BR>The reply is awaited.
Annuouncement under Regulation 30 of SEBI (LODR) Regulations, 2015 - Clarification on Significant increase in the volume of security.
Annual General Meeting of the Company will be held on Tuesday, 11th August 2026.
Intimation of Transfer of Equity Shares to IEPF Authority in respect of unclaimed dividend for the financial year 2018-19.
Submission of advertisement published in newspapers regarding notice for transfer of equity shares and unclaimed dividends to Investor Education and Protection Fund (IEPF) Account.
Annual Secretarial Compliance Report dated May 22, 2026 for the year ended March 31, 2026.
Financial results for quarter and year ended March 31, 2026, published in the newspaper on May 23, 2026.
Audited Financial Results for the year ended 31st March 2026
Outcome of Board Meeting
Unichem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2026 ,inter alia, to consider and approve to consider and approve ....
Pl. find attached herewith announcement under Reg. 30.
Announcement under Regulation 30 (LODR) - Credit Rating
Certificate u/r 74(5) of SEBI (DP) regulations, 2018 for the quarter ended 31st March 2026
Please find enclosed Results of Postal Ballot and Scrutinizers'' Report
Closure of Trading Window
Announcement under Regulation 30 (LODR) - Change in Directorate.
Postal ballot notice publication dated 26th February 2026.
Postal Ballot Notice.
Financial Results for the quarter and nine months ended December 31, 2025, published in the newspaper on February 6, 2026.
Disclosure u/r. 30 0f SEBI Listing Regulations
Outcome of Board Meeting held today, i.e. Thursday, February 5, 2026
Financial Results
Appointment of Dr. (Ms.) Swati Patankar as a Non-Executive Independent Director
USPDA inspected Company''s Kolhapur API facility from January 26, 2026, to February 2, 2026.
Final report on re-lodgement of transfer requests of physical shares from 1st December 2025 upto 6th January 2026
Announcement under Reg. 30 of Listing Regulations
Compliance Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018 for the quarter ended December 31, 2025.
Unichem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2026 ,inter alia, to consider and approve This is to inform you ....
Intimation of Closure of Trading Window.
5th Report on re-lodgement of Transfer Request of Physical Shares for the month ended 30th November 2025.
4th Report on Re-Lodgement of Transfer Requests of Physical Shares for the month ended 31st October 2025.
Financial Results for Quarter and Half Year ended 30th September 2025
Annual Reports
15Credit Ratings
6Concalls
6Jun 2017
30 Jun 2017Feb 2017
28 Feb 2017Nov 2016
30 Nov 2016Aug 2016
31 Aug 2016Jun 2016
30 Jun 2016Feb 2016
29 Feb 2016Held by ETFs
1 ETFs hold unichemlab · sorted by weight
Held by Mutual Funds
3 schemes hold unichemlab · sorted by weight